Your browser doesn't support javascript.
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.
Branche, Angela R; Rouphael, Nadine G; Losada, Cecilia; Baden, Lindsey R; Anderson, Evan J; Luetkemeyer, Anne F; Diemert, David J; Winokur, Patricia L; Presti, Rachel M; Kottkamp, Angelica C; Falsey, Ann R; Frey, Sharon E; Rupp, Richard; Bäcker, Martín; Novak, Richard M; Walter, Emmanuel B; Jackson, Lisa A; Little, Susan J; Immergluck, Lilly C; Mahgoub, Siham M; Whitaker, Jennifer A; Babu, Tara M; Goepfert, Paul A; Fusco, Dahlene N; Atmar, Robert L; Posavad, Christine M; Netzl, Antonia; Smith, Derek J; Telu, Kalyani; Mu, Jinjian; Makowski, Mat; Makhene, Mamodikoe K; Crandon, Sonja; Montefiori, David C; Roberts, Paul C; Beigel, John H.
  • Branche AR; University of Rochester VTEU, Rochester, NY, USA.
  • Rouphael NG; Emory University Hope Clinic, Decatur, GA, USA.
  • Losada C; Emory University Hope Clinic, Decatur, GA, USA.
  • Baden LR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Anderson EJ; Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA, USA.
  • Luetkemeyer AF; Zuckerberg San Francisco General, University of California San Francisco, San Francisco, CA, USA.
  • Diemert DJ; George Washington Vaccine Research Unit, George Washington University, Washington DC, USA.
  • Winokur PL; University of Iowa College of Medicine, Iowa City, IA, USA.
  • Presti RM; Washington University School of Medicine, St. Louis, MO, USA.
  • Kottkamp AC; NYU VTEU Manhattan Research Clinic at NYU Grossman School of Medicine, New York, NY, USA.
  • Falsey AR; University of Rochester VTEU, Rochester, NY, USA.
  • Frey SE; Saint Louis University, Center for Vaccine Development, St. Louis, MO, USA.
  • Rupp R; University of Texas Medical Branch, Galveston, TX, USA.
  • Bäcker M; NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, NY, USA.
  • Novak RM; University of Illinois at Chicago-Project WISH, Chicago, IL, USA.
  • Walter EB; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
  • Little SJ; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA.
  • Immergluck LC; Morehouse School of Medicine, Atlanta, GA, USA.
  • Mahgoub SM; Howard University College of Medicine, Howard University Hospital, Washington DC, USA.
  • Whitaker JA; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Babu TM; Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Goepfert PA; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Fusco DN; Tulane University School of Medicine, New Orleans, LA, USA.
  • Atmar RL; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Posavad CM; IDCRC Laboratory Operations Unit - Fred Hutchinson Cancer Center and University of Washington, Seattle, WA, USA.
  • Netzl A; Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK, USA.
  • Smith DJ; Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK, USA.
  • Telu K; The Emmes Company, LLC, Rockville, MD, USA.
  • Mu J; The Emmes Company, LLC, Rockville, MD, USA.
  • Makowski M; The Emmes Company, LLC, Rockville, MD, USA.
  • Makhene MK; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Crandon S; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Montefiori DC; Duke University, Durham, NC, USA.
  • Roberts PC; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Beigel JH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Clin Infect Dis ; 2023 Apr 10.
Article in English | MEDLINE | ID: covidwho-2292557
ABSTRACT
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2023 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal subject: Communicable Diseases Year: 2023 Document Type: Article Affiliation country: Cid